RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:98845

Classic Hodgkin lymphoma, lymphocyte-rich type

high confidenceSubtype of disorder

Publications

256

73.6th percentile

Trials

4

Interventional, condition-specific

Researchers

1,310

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (13)

Hodgkin lymphoma, lymphocyte-rich · Hodgkin's disease, lymphocyte predominance [obs] · LRCHL · classic Hodgkin lymphoma, lymphocyte-rich type · lymphocyte rich Hodgkin lymphoma · lymphocyte rich Hodgkin's disease · lymphocyte rich Hodgkin's lymphoma · lymphocyte rich classical Hodgkin lymphoma · lymphocyte rich classical Hodgkin's disease · lymphocyte rich classical Hodgkin's lymphoma · lymphocyte-rich Classic Hodgkin lymphoma · lymphocyte-rich classical Hodgkin lymphoma · lymphocyte-rich classical Hodgkin's lymphoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    256 matched papers (148 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    4 matched on ClinicalTrials.gov

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

256

256 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

256 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

148 in the last 10 years · high confidence · 73.6th percentile (publications denominator)

Phrase hits: 256 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,310

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Jaffe ES12 papers · 2024

    Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. elainejaffe@nih.gov

    Papers in Europe PMC
  2. 02
    Nakamura S7 papers · 2023

    Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan.

    Papers in Europe PMC
  3. 03
    Satou A6 papers · 2023

    Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan.

    Papers in Europe PMC
  4. 04
    Takahara T5 papers · 2023

    Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan.

    Papers in Europe PMC
  5. 05
    Engert A4 papers · 2019

    First Department of Internal Medicine and German Hodgkin Study Group, University Hospital of Cologne, Germany.

    Papers in Europe PMC
  6. 06
    Harris NL4 papers · 2016

    Department of Pathology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Warren Building 2nd floor, Boston, MA 02114 USA.

    Papers in Europe PMC
  7. 07
    Pileri SA4 papers · 2022

    Haematopathology Division, European Institute of Oncology-IEO IRCCS Milan, 20141 Milan, Italy.

    Papers in Europe PMC
  8. 08
    Piris MA4 papers · 2023

    Pathology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.

    Papers in Europe PMC
  9. 09
    Swerdlow SH4 papers · 2022

    Department of Pathology, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, PA.

    Papers in Europe PMC
  10. 10
    Ascani S3 papers · 2021

    Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, 05100 Terni, Italy.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

4

interventional trials for this specific condition

4 interventional trials matched this specific condition name; none in our sample are currently recruiting. 43 trials are registered for classic Hodgkin lymphoma, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

4 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 86.7th percentile).

high confidence · 86.7th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

4 interventional trials matched after quoted-phrase search and title/condition post-filter.

No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.

Broader category: classic Hodgkin lymphoma

43

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Classic Hodgkin lymphoma, lymphocyte-rich type" OR "Hodgkin lymphoma, lymphocyte-rich" OR "Hodgkin's disease, lymphocyte predominance [obs]" OR "LRCHL" OR "lymphocyte rich Hodgkin lymphoma" OR "lymphocyte rich Hodgkin's disease" OR "lymphocyte rich Hodgkin's lymphoma" OR "lymphocyte rich classical Hodgkin lymphoma" OR "lymphocyte rich classical Hodgkin's disease" OR "lymphocyte rich classical Hodgkin's lymphoma" OR "lymphocyte-rich Classic Hodgkin lymphoma" OR "lymphocyte-rich classical Hodgkin lymphoma" OR "lymphocyte-rich classical Hodgkin's lymphoma"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Classic Hodgkin lymphoma, lymphocyte-rich type" OR "Hodgkin lymphoma, lymphocyte-rich" OR "Hodgkin's disease, lymphocyte predominance [obs]" OR "LRCHL" OR "lymphocyte rich Hodgkin lymphoma" OR "lymphocyte rich Hodgkin's disease" OR "lymphocyte rich Hodgkin's lymphoma" OR "lymphocyte rich classical Hodgkin lymphoma" OR "lymphocyte rich classical Hodgkin's disease" OR "lymphocyte rich classical Hodgkin's lymphoma" OR "lymphocyte-rich Classic Hodgkin lymphoma" OR "lymphocyte-rich classical Hodgkin lymphoma" OR "lymphocyte-rich classical Hodgkin's lymphoma"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 4 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"classic Hodgkin lymphoma"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T05:34:37.492Z